MEDIA ADVISORY: Metabolife Renews its Call for Strong FDA Regulation of Ephedra


Home

MEDIA ADVISORY

 

ATTENTION HEALTH AND MEDICAL REPORTERS

A Medical News Special Report

 

METABOLIFE RENEWS ITS CALL FOR STRONG FDA REGULATION OF EPHEDRA

COMPANY TELLS SENATE GOVERNMENT AFFAIRS SUBCOMMITTEE

THAT METABOLIFE 356 IS SAFE AND EFFECTIVE WHEN USED AS DIRECTED

 

 

WHO:             SENATE GOVERNMENTAL AFFAIRS COMMITTEE, Oversight of Government Management, Restructuring and the District of Columbia Subcommittee

 

WHAT:           EPHEDRA OVERSIGHT HEARING

 

WHEN:           TUESDAY, OCTOBER 8, 2002

 

WHY:              OBESITY HAS REACHED EPIDEMIC PROPORTIONS. MORE THAN 25% OF ADULTS ARE OVERWEIGHT AND OBESE. BEING OVERWEIGHT AND OBSE ARE MAJOR HEALTH RISKS TO AMERICANS.

 

THE APRIL 25, 2002 EDITION OF PRESTIGIOUS INTERNATIONAL JOURNAL OF OBESITY, PUBLISHED A LONG-TERM CLINICAL TRIAL OF EPHEDRA CONDUCTED BY RESEARCHERS AT COLUMBIA UNIVERSITY AND HARVARD MEDICAL SCHOOL.  THE RESEARCHERS CONCLUDED THAT “HERBAL EPHEDRA/CAFFEINE PROMOTED BODY WEIGHT AND BODY FAT REJECTION AND IMPROVED BLOOD LIPIDS WITHOUT SIGNIFICANT ADVERSE EVENTS.”

 

EXPERTS AGREE THAT SIGNIFICANT HEALTH BENEFITS MAY BE OBTAINED BY A 5-10% WEIGHT LOSS.  METABOLIFE 356 IS SAFE AND EFFECTIVE WHEN USED AS DIRECTED.

 

METABOLIFE WOULD WELCOME THE OPPORTUNITY TO DISCUSS THIS ISSUE WITH YOU.  FOR MORE INFORMATION AND INTERVIEWS CONTACT JAN STRODE, 619.890.4040

Powered By Traffic Booster Absolute News Manager Plug-in by Xigla Software

This article has been moved here